Yingying Zhu1, Xin Xia1, Neil Gross2, Kristina R Dahlstrom2, Liming Gao1, Zhiyong Liang3, Zhiqiang Gao1, Peng Wei4, Chuan Liu5, Guojun Li2, Yuncheng Li6, Xingming Chen1. 1. Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. 2. Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. 4. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 6. Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract
BACKGROUND: The purpose of this study was to investigate significance of HPV16 DNA/p16 for survival of patients with laryngeal squamous cell carcinoma (LSCC). METHODS: HPV16 DNA and p16 status in 812 LSCC patients were determined. The survival was performed using Kaplan-Meier estimates and Cox model. RESULTS: Compared with HPV negativity, adjusted HRs for HPV16 positivity were 0.57, 95% CI, 0.38 to 0.87; 0.60, 0.40 to 0.88; and 0.65, 0.46 to 0.94 for disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS), respectively. Additionally, for p16 expression, aHRs were 0.68, 95% CI, 0.48 to 0.96; 0.72, 0.52 to 0.98; and 0.73, 0.54 to 0.99 for DSS, RFS, and OS, respectively. Finally, for combined analysis, patients with both HPV16-positivity/p16-positivity had much better prognosis than those with either negativity. Such above survivals are more significantly better in never smokers. CONCLUSION: Our findings suggest that HPV16/p16 may affect survival outcomes of LSCC patients, particularly in never smokers.
BACKGROUND: The purpose of this study was to investigate significance of HPV16 DNA/p16 for survival of patients with laryngeal squamous cell carcinoma (LSCC). METHODS:HPV16 DNA and p16 status in 812 LSCCpatients were determined. The survival was performed using Kaplan-Meier estimates and Cox model. RESULTS: Compared with HPV negativity, adjusted HRs for HPV16 positivity were 0.57, 95% CI, 0.38 to 0.87; 0.60, 0.40 to 0.88; and 0.65, 0.46 to 0.94 for disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS), respectively. Additionally, for p16 expression, aHRs were 0.68, 95% CI, 0.48 to 0.96; 0.72, 0.52 to 0.98; and 0.73, 0.54 to 0.99 for DSS, RFS, and OS, respectively. Finally, for combined analysis, patients with both HPV16-positivity/p16-positivity had much better prognosis than those with either negativity. Such above survivals are more significantly better in never smokers. CONCLUSION: Our findings suggest that HPV16/p16 may affect survival outcomes of LSCCpatients, particularly in never smokers.